Go Pro
NASDAQ:HELP

Cybin Q1 2027 Earnings Report

Cybin logo
$11.70 -0.21 (-1.76%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$11.79 +0.09 (+0.76%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cybin EPS Results

Actual EPS
-$0.91
Consensus EPS
-$0.80
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Q1 2027
Time
Before Market Opens
Conference Call Date
Friday, August 14, 2026
Conference Call Time
4:00PM ET

Earnings Documents

Cybin Earnings Headlines

Cybin (NASDAQ:HELP) Stock: Insider Greg Cavers Buys 3,000 Shares
Cybin (NASDAQ:HELP) Downgraded by Wall Street Zen to Strong Sell
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Helus Pharma Announces Completion of Legal Name Change
Helus Pharma Announces Completion of Legal Name Change
Cybin Inc (HELP)
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP) is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin therapy being studied for major depressive disorder, and CYB004, an investigational formulation of N,N-dimethyltryptamine (DMT) being evaluated for generalized anxiety disorder. Its programs are intended to support shorter, more controlled treatment sessions than traditional psychedelic therapies.

Founded in 2019 and headquartered in Toronto, Cybin has conducted research and clinical-development activities in North America and the United Kingdom. The company has been led by Chief Executive Officer Doug Drysdale, who has experience in biotechnology and pharmaceutical development. Cybin’s shares have historically traded on Nasdaq under the symbol CYBN; the symbol HELP may refer to a different listed company.

View Cybin Profile